

S2 Table

Plasmid	Description	Cloning vector	Reference	Source
MN.3	MN.3 Env expression plasmid	unknown	Burioni <i>et al.</i> 2008 PLoS One. 3(10):e3423	J. Mascola, Vaccine Research Center, National Institutes of Health, Bethesda, USA
BaL.01	BaL.01 Env expression plasmid	pcDNA3.1D/V5-His-TOPO	Li <i>et al.</i> 2006 J Virol. 80(3):1414-26	J. Mascola*, Vaccine Research Center, National Institutes of Health, Bethesda, USA
BaL.01 SOS**	BaL.01 SOS Env expression plasmid	pcDNA3.1D/V5-His-TOPO	Li <i>et al.</i> 2006 J Virol. 80(3):1414-26	J. Mascola*, Vaccine Research Center, National Institutes of Health, Bethesda, USA
JR-FL	JR-FL Env expression plasmid	pcDNA3.1/V5-His-TOPO	Rusert <i>et al.</i> 2009 AIDS. 23(11):1319-27	N/A
BG505_T332N**	BG505.W6M.ENV.C2_T332N Env expression plasmid	pcDNA3.1/V5-His-TOPO	Wu <i>et al.</i> 2006 J Virol. 80(2):835-44	Julie Overbaugh*, Fred Hutchinson Cancer Research Center, Seattle, USA
pCMV-rev	HIV-1 Rev expression plasmid	pCMV	Lewis <i>et al.</i> 1990 J Virol. 64(4):1690-7	M. Hammar skjöld and D. Rekosh*, The Scripps Research Institute, La Jolla, USA
pNL-lucAM	Partial Δenv HIV-1 pseudotyping vector with firefly luciferase reporter gene	pNL4-3	Pugach <i>et al.</i> 2007 Virology. 361(1):212-28	A. Marozsan and J. Moore, Weill Medical College, Cornell University, New York, USA
sCD4-183_avi_his	Recombinant soluble CD4 expression plasmid	pET-32a(+)	This study	N/A
pBirAcm	BirA biotin ligase expression plasmid	pACYC-184		Avidity LLC
<p>* Through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH</p> <p>** The SOS mutations (A501C/T605C) and the T332N mutation was introduced with QuikChange II XL Site-Directed Mutagenesis Kit (Agilent Technologies, Santa Clara, USA) according to manufacturer's instructions</p>				